Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: Pharm Res. 2024 Feb 1;41(3):557–566. doi: 10.1007/s11095-024-03662-w

Table 1:

Pharmacokinetics of raloxifene and raloxifene-6-glucuronide in the absence and presence of orally administered test articles (n=5 per time point)

Vehicle Green tea extract EGCG
Raloxifene
Cmax (nM) 140 (22) 79 (20)** 168 (30)
AUC0-4h (nM•h) 341 (16) 200 (19) 322 (80)
AUCR0-4h NA 0.59 (0.46 – 0.74) 0.94 (0.44 – 2.01)
AUC0-24h (nM•h) 867 (31) 669 (14) 867 (18)
AUCR NA 0.77 (0.6 – 1) 1.01 (0.65 – 1.55)
tmax (h) 2 (0.25 - 4) 4 (1 - 6) 0.5 (0.25 - 2)
Raloxifene-6-glucuronide
Cmax (nM) 700 (44) 288 (33)** 820 (35)
AUC0-4h (nM•h) 935 (33) 624 (31) 1200 (53)
AUCR0-4h NA 0.67 (0.40 – 1.12) 1.29 (0.8 – 2.07)
AUC0-24h (nM•h) 1930 (24) 1560 (32) 2150 (52)
AUCR0-24h NA 0.81 (0.50 - 1.30) 1.11 (0.65 – 1.91)
tmax (h) 0.25 (0.25 - 0.5) 0.25 (0.25 - 0.5) 0.5 (0.25 - 4)
Metabolite-to-parent 2.74 (30) 3.12 (34) 3.74 (25)
AUC0-4h ratio
Metabolite-to-parent 2.23 (36) 2.33 (24) 2.48 (38)
AUC0-24h ratio

Values are geometric mean (CV%). AUCR values are geometric means (90% confidence interval), and tmax are median (range). CV, coefficient of variation; Cmax, maximum plasma concentration; AUC0-4h, area under the plasma concentration-time curve from 0 to 4 h; AUC0-12h, AUC from 0 to 12 h; tmax, time to Cmax; NA, not applicable. ** p < 0.01 compared to vehicle by 1-way ANOVA with Dunnett’s post-test.